Featured Studies Results

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

https://www.facingourrisk.org/research-clinical-trials/study/395 /low-dose-tamoxifen-with-or-without-omega-3-fatty-acids-for-breast-cancer-risk-reduction

Clinicaltrials.gov identifier:
NCT06195306 (https://clinicaltrials.gov/show/NCT06195306)

Prevention
Phase 2 study for overweight postmenopausal women at increased risk for breast cancer

---

A Study of Fallopian Tube Removal with Delayed Ovary Removal to Lower Ovarian Cancer Risk (TUBA-WISP-II)

https://www.facingourrisk.org/research-clinical-trials/study/404 /

Clinicaltrials.gov identifier:
NCT04294927 (https://clinicaltrials.gov/show/NCT04294927)

Prevention
Prevention study for women at high risk for ovarian cancer

---

PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease

https://www.facingourrisk.org/research-clinical-trials/study/291 /patrol-study-prostate-cancer-screening-for-people-at-genetic-risk-for-aggressive-disease

Clinicaltrials.gov identifier:
NCT04472338 (https://clinicaltrials.gov/show/NCT04472338)

Prevention
Screening study for people with a mutation linked to prostate cancer risk

---

Screening Study for Men at High Genetic Risk for Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/72 /men-at-high-genetic-risk-for-prostate-cancer

Clinicaltrials.gov identifier:
NCT03805919 (https://clinicaltrials.gov/show/NCT03805919)

Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation

---

Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE)

https://www.facingourrisk.org/research-clinical-trials/study/138 /validating-a-blood-test-for-early-ovarian-cancer-detection-in-high-risk-women-and-families

Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation

---

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High-Risk Women

https://www.facingourrisk.org/research-clinical-trials/study/205 /risk-reducing-salpingectomy-with-delayed-oophorectomy-as-an-alternative-to-risk-reducing-salpingo-oophorectomy-in-high-risk-women

Clinicaltrials.gov identifier:
NCT05287451 (https://clinicaltrials.gov/show/NCT05287451)

Prevention
Prevention study for women at high risk for ovarian cancer

---

Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

https://www.facingourrisk.org/research-clinical-trials/study/180 /prostate-cancer-genetic-risk-evaluation-and-screening-study-progress

Clinicaltrials.gov identifier:
NCT05129605 (https://clinicaltrials.gov/show/NCT05129605)

Prevention
People at high risk for prostate cancer due to an inherited mutation

---

Helping Latinas Understand Their Risk for Breast Cancer and Get Breast Cancer Care

https://www.facingourrisk.org/research-clinical-trials/study/250 /helping-latinas-understand-their-risk-for-breast-cancer-and-get-breast-cancer-care

Clinicaltrials.gov identifier:
NCT05483283 (https://clinicaltrials.gov/show/NCT05483283)

Prevention
Latinas with a high risk of breast cancer

---